entertainment -WSS

entertainment

author：leisure time 2025-10-02 01:12:46 - browse：4

The New York Stock Exchange (NYSE) — Spencer Platt/Getty Images

Biohaven Pharmaceuticals said Wednesday that a new type of experimental medicine reduced levels of a disease-causing immune molecule by up to 37% in an early-stage study of human volunteers — a result that the company called “positive” as a proof of concept but that also fell short of investor expectations.

The drug, called BHV-1300, belongs to a new class of antibody medicines that shuttle harmful proteins to the liver so they can be removed from the body. BHV-1300 is specifically designed to reduce levels of an autoantibody called IgG that is implicated in rheumatoid arthritis, myasthenia gravis, and other autoimmune disorders.

In its Phase 1 study, Biohaven tested four escalating doses of BHV-1300 in healthy volunteers, showing a reduction in levels of IgG of 5%, 15%, 30%, and 37%, respectively, the company said. The reductions in IgG levels, which occurred relatively quickly in just four to five days, did not cause significant, adverse changes in liver enzyme levels, Biohaven added — an important safety check given the mechanism of the drug.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： FDA advisers back CAR

WSS

Ebola: Gilead Sciences antiviral shows promise as new treatment

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

What to know about 'Guardians of the Galaxy Vol. 3' as it hits Disney+

'Cuddling' is just what the doctor ordered for a 200

Medical schools are missing the mark on artificial intelligence

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

focus

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Drug repurposing or repositioning? The language matters

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

State Dept. review finds Biden bears some blame for Afghanistan failures

Judge in Trump's Jan. 6 case gives attorneys 2 weeks to propose trial date

Peter Hotez and the public health issue of online harassment

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Activists slam private health insurers over coverage restrictions

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

ChatGPT in medicine: STAT answers readers' burning questions

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

knowledge

Russian court extends detention of American musician

Medical mystery: When an infection after surgery isn’t what it seems

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

Ebola: Gilead Sciences antiviral shows promise as new treatment

R.J. Reynolds sues to protect 'crisp' cigs from California flavor ban

Pushing for an NIH office for post

focus

explore

knowledge

focus